Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy?
The occurrence of generalised tonic-clonic seizures (GTCS) was investigated in patients with absence epilepsy (AE), evaluating the opinion that ethosuximide does not protect against GTCS. Our retrospective study included 238 patients with absences and generalised 3-Hz spike waves (SW). We analysed the efficacy of antiepileptic drugs (AED) and the occurrence of GTCS before, during and after treatment. We surveyed family history, treatment delay and EEG findings. Family history of epilepsy was positive in 28%. Children with 3-Hz SW lasting >10 s suffered less frequently from GTCS (p=0.002). Photosensitivity (3-Hz SW during photic stimulation) recorded in 47 children was more frequent in juvenile AE (p=0.0001), but not associated with higher rates of GTCS. GTCS occurred in 27 children (11%) before treatment, in 14 (5.8%) during treatment and in 8 (4.8%) after tapering AED. Valproate and ethosuximide monotherapy were equally effective on absences, carrying the same low risk of GTCS during
Related Questions
- I would like to use HeartScore® with patients who suffer from diabetes; however, HeartScore® does not include diabetes as an independent risk factor. How do I accommodate these patients?
- Is induced abortion with misoprostol a risk factor for late abortion or preterm delivery in subsequent pregnancies?
- Is metabolic syndrome a risk factor for colorectal adenoma?
